News

Dealbreaker on MSN5h
BioNTech to Pay $740M-Plus to Settle mRNA Patent Disputes, Smooth $1.25 Billion Deal
W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...
Pharmaceutical Commerce10h
Pharma Pulse: FDA Launches Pre-Check Program, GSK Secures mRNA Settlement, and Pharma Leaders Eye US Investment Boost
This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...
InvestorsHub on MSN12h
GSK shares rise after FDA grants priority review for oral gonorrhea antibiotic
GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...
GSK climbs after winning FDA priority review for oral gonorrhoea antibiotic
GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...
pharmaphorum14h
Vinay Prasad returns to FDA
The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...
CureVac Resolves Patent Litigation with Pfizer/BioNTech
CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...